- Report
- November 2024
- 65 Pages
Global
From €4620EUR$4,995USD£3,856GBP
- Report
- August 2024
- 53 Pages
Global
From €4620EUR$4,995USD£3,856GBP
- Report
- June 2021
- 55 Pages
Global
From €4620EUR$4,995USD£3,856GBP
- Report
- October 2025
- 160 Pages
Global
From €2923EUR$3,160USD£2,439GBP
€3653EUR$3,950USD£3,049GBP
- Report
- August 2026
- 43 Pages
United States
From €518EUR$560USD£432GBP
€647EUR$700USD£540GBP
- Report
- December 2022
- 59 Pages
China
From €4620EUR$4,995USD£3,856GBP
- Report
- December 2023
- 93 Pages
Global
From €3500EUR$4,054USD£3,023GBP
Contract dose manufacturing is a service provided by pharmaceutical companies to produce drugs and other pharmaceutical products. It involves the production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for customers. Contract dose manufacturing is a cost-effective way for pharmaceutical companies to outsource the production of their products. It also allows them to focus on their core competencies, such as research and development, while leaving the manufacturing to a third-party. Contract dose manufacturing is a highly regulated process, with strict quality control measures in place to ensure the safety and efficacy of the products.
Some of the companies in the contract dose manufacturing market include Boehringer Ingelheim, Catalent, Lonza, Patheon, Recipharm, and Vetter. Show Less Read more